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Poster Session II S349MUDand RD recipients; respectively. MUD recipients had a higher
cumulative incidence of non- relapse mortality at 2 years of 34%
compared to 19% for RD recipients.
Conclusions:Outcomes afterMUDHCTwhen performed at com-
munity cancer centers were not inferior to outcomes after RDHCT.
It seems feasible to perform MUD HCT at community cancer cen-
ters with outcomes comparable to published literature.Mud (%) RD (%) p
Number 30 26
Median Age (Range) 55.86 (23-71) 53.8 (35-73) 0.18
Gender (F/M), % (10/30), 33.3% (13/26), 50% 0.32
Median CD 34 cell
dose (Range)
7.18 (1.89-11.35) 7.04 (2.87-10.4) 0.16
Diagnosis (Acute leukemia
Vs Others)
0.83
ALL 2 ( 7%) 7 (27%)
AML/MDS 19 (63%) 11 (42%)
Multiple Myeloma 0 3 (11%)
CLL/T-PLL 1/1 (7%) 1/1 (8%)
HD/NHL 1/2 (10%) 1/1 (8%)
MF 1 (3%) 1 (4%)
SAA 2 (7%) 0
CML 1 (3%) 0
Status at Transplant 0.21
CR1 13 (43%) 7 (27%)
CR2 or beyond 6 (20%) 3 (11.5%)
PR 2 (7%) 3 (11.5%)
Persistent/Progressive
Disease
6/2 (27%) 5/5 (38.5%)
Primary Refractory 1 (3%) 3 (11.5%)
Cytogenetics 0.86
Normal Cytogenetics 12 (40%) 12 (46%)
High Risk Cytogenetics 18 (60%) 14 (54%)
Prior Transplant
Autologous 1 5
Allogeneic 2 1
Co-Morbidity Index 0.84
CCI 1-2 10 (33%) 8 (31%)
CCI 3 or more 20 (67%) 18 (69%)
Distance From Transplant
Center
0.43
Median 21.2 miles 23.1 miles
Range 5-131 miles 4.9-130 miles
Conditioning Regimens 0.39
RIC/NMA 15 (50%) 17 (65%)
FIC 15 (50%) 9 (35%)
MF indicates myelofibrosis; RIC, reduced intensity conditioning; FIC, full
intensity conditioning; NMA, non-myeloablative.391
HAPLOIDENTICAL TRANSPLANT WITH HIGH DOSE OF UNMANIPULATED
CD34, IN VIVO T CELL DEPLETION WITH ALEMTUZUMAB AND RIC REG-
IMEN. GOOD ENGRAFTMENT RATE, LOW GVHD INCIDENCE AND EN-
COURAGING SURVIVAL. SINGLE CENTER EXPERIENCE IN COLOMBIA
Karduss, A.J., Coll, Y., Alejo, J., Rodolfo, G.L., Pedro, R., Hilda, D.,
Hurtado, L. Instituto de Cancerologia- Clinica las Americas, Medellin,
Colombia
For a successful haploidentical transplant is necessary to overcome
the HLA barrier. We present our experience using high dose of un-
manipulated CD34, in vivo T cell depletion and a RIC regimen.
After a signed inform consent seventeen patients received 20 trans-
plants (3 ptes. underwent a second haplo transplant after engraft-
ment failure of the first). 9 were women, median age was 17.3
years (7-36), 40% were under sixteen. 5 patients had high risk
AML CR1 or CR 2; 3 had high risk ALL CR1 or CR3; 5 heavily
transfused Fanconi anemia,1 aplastic anemia,1 myelofibrosis, 1den-
dritic cell leukemia CR2, 1 hemophagocytic linphohistiocytosis.Two patients received the haplo transplant after an unsuccessful
cord blood transplant. The donors were 16 mothers, 3 siblings and
1 father. 80% had 3 out of 6 match.
The conditioning was cyclophosphamide 2000 mgs/m2, fludara-
bine 120 mgs/m2 +/- thiothepa 5 mgs/kg. In 11 procedures TBI
200-400 Cgy was added. In vivo T cell depletion was done with
Alemtuzumab 0.2 mg/kg/day from day -4 to cero. All patients re-
ceived unmanipulated peripheral blood CD34 obtained by apheresis
(median 12 mill/kg) in 2 cases bone marrow was added. The GVHD
prophylaxis was accomplished with CyA for 180 days and MMF for
30. Filgrastimwas administered fromD+6 until neutrophil recovery.
Neutrophil engraftment occurred at median of 11 days (9-14) in
82% of the patients after first transplant and in 100% after the sec-
ond, 1 patient had a secondary graft failure. The incidence of acute
GVHDGI-II was 25%, there were no cases of GIII-IV. One patient
had aGVHDGIII after DLI, chronic GVHDwas presented in 40%
of the patients, in all cases limited, and in 50% of them treated with
only topical medication.
The 100 days mortality was 17.64 % and with a median follow up
of 16 months (1-38) the overall survival was 53.5%.
Conclusion:The strategy of use high dose of unmanipulated CD34,
in vivo T cell depletion and a RIC preparative regimen produce a re-
liable engraftment, low incidence of GVHD, low day 100 mortality
and good overall survival in this high risk group. It deserve more
studies.392
EARLY HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ALL PA-
TIENTS AFTER REDUCED INDUCTION CHEMOTHERAPY
Ghavamzadeh, A., Alimoghaddam, K., Pourkhani, H., Jahani, M.,
Mousavi, S.A., Bahar, B., Iravani, M., Jalili, M., Derakhshandeh, R.,
Jalali, A. Tehran University of Medical Sciences, Tehran, Islamic Republic
of Iran
Hematopoietic stem cell transplantation (HSCT) is only curable
treatment in ALL patients. However, the efficacy of induction, con-
solidation chemotherapy and early hematopoietic stem cell trans-
plantation remain unclear.
Therefore, at our center, patients with newly diagnosed ALL,
are randomly divided into 2 arms from 2008 to 2011. Patients in
the study arm received reduced induction chemotherapy (vincris-
tine 1 mg/m2 every week for 4 weeks plus dexamethasone 24mg/
d for 28 days) and undergone early HSCT after disease stabilized
within 15-30 days without intention of achieving complete remis-
sion (CR). The control arm received conventional chemotherapy
followed by HSCT. Both arms received busulfan (4mg/kg for 4
days) plus cyclophosphamide (60mg/kg for 2 days) as a condition-
ing regimen. Here, we compare the efficacy of these two kinds of
treatment.
A total of 90 patients enrolled in the study. Eighteen patients al-
located to the study arm and 72 others allocated to the control arm.
The median age was 21.5 years (range: 16-33) in the study arm and
22 years (range: 3-49) in the control arm. All patients underwent
Allogeneic HSCT with peripheral blood source. The median wait-
ing time from diagnosis to HSCT was 217 days (range: 45-708) in
the control arm. In the study arm, 14 patients (78%) were in CR1.
The median follow-up time was 15.5 months (range: 2-32) in the
study arm and 12.5 months (range: 1-39) in the control arm. Re-
lapse occurred in 2 (11.1%) and 6 (8.3%) patients of the study
and the control arms, respectively. Five patients (27.7%) of the
study arm and 10 patients (13.5%) of the control arm were died.
The causes of death were GVHD and sepsis in 3 (60%) patients
and relapse in 2 (40%) patient in the study arm. The causes of
death were GVHD in 6 (60%) patients and relapse in 4 (40%) pa-
tients in the control arm. One-year overall survival was 81.9% (SE:
9.5%) and 84.8% (SE: 4.8%) in study and control arms, respec-
tively (p 5 0.221). One-year disease-free survival was 81.9% (SE:
9.5%) and 82.4% (SE: 4.9%) in study and control group, respec-
tively (p 5 0.532).
Reduced induction followed by early transplantation without con-
solidation reveals no significant statistical different outcome com-
pared with routine treatment. This result might be due to small
size of patients and short time of follow-up. A study with more cases
and long time follow-up is recommended.
